Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability

2013 ◽  
Vol 34 (10) ◽  
pp. 3159-3167 ◽  
Author(s):  
Arlette Scheifes ◽  
Daniël de Jong ◽  
Joost Jan Stolker ◽  
Henk L.I. Nijman ◽  
Toine C.G. Egberts ◽  
...  
2019 ◽  
Vol 13 (1) ◽  
pp. 31-40 ◽  
Author(s):  
David Branford ◽  
David Gerrard ◽  
Nigget Saleem ◽  
Carl Shaw ◽  
Anne Webster

Purpose The programme – Stopping the over-medication of people with an intellectual disability, Autism or Both (STOMP) is a three-year programme supported by NHS England. Concern about the overuse of antipsychotic drugs has been a constant theme since the 1970s. However, despite a multitude of guidelines the practice continues. The report into the events at Winterbourne View not only raised concerns about the overuse of antipsychotic drugs but of antidepressants and multiple psychotropic drug use. The purpose of this paper is twofold: Part 1 is to present the history and background to the use of psychotropic drugs in intellectual disabilities, autism or both; and Part 2 presents the progress with the STOMP programme. Design/methodology/approach The review tracks the various concerns, guidelines and attempts to tackle the issue of over medication of people with intellectual disability autism or both. Findings The review identifies that despite the many studies and guidelines associated with the prescribing of psychotropic drugs for people with an intellectual disability, autism or both the practice is common. Programmes that minimise the use of psychotropic drugs involve a full use of the multidisciplinary team and an availability of alternative methods of managing challenging behaviours. Originality/value STOMP is part of an English national agenda – Transforming care. The English Government and leading organisations across the health and care system are committed to transforming care for people with intellectual disabilities, autism or both who have a mental illness or whose behaviour challenges services. This review identifies many studies, programmes and guidelines associated with psychotropic drug use for people with an intellectual disability, autism or both.


2018 ◽  
Vol 7 (10) ◽  
pp. 339 ◽  
Author(s):  
Lotte Rasmussen ◽  
Niels Bilenberg ◽  
Martin Thomsen Ernst ◽  
Sidsel Abitz Boysen ◽  
Anton Pottegård

Children with autism spectrum disorder (ASD) have a considerable use of psychotropics. Leveraging nationwide registry data, we aimed to describe the use of psychotropics among children and adolescents with ASD in Denmark. Use of melatonin and attention-deficit/hyperactivity disorder (ADHD) medication increased from 2010 to 2017, while there were limited changes in use of antidepressants and antipsychotics. Thirty percent of the identified children used psychotropics in 2017 most commonly ADHD medication (17%) and melatonin (13%). Methylphenidate, sertraline and risperidone were most often prescribed. Most children filled more than one prescription and, across drug classes, at least 38% received treatment two years after treatment initiation. Use of psychotropics followed psychiatric comorbidities. Comorbidities did not affect age at treatment initiation. Use of psychotropics varied according to age and sex with limited use in the youngest children. In summary, psychotropic drug use has increased in children with ASD mainly due to an increase in the use of ADHD medication and melatonin. In accordance with previous studies, use seems to follow comorbidities. The long treatment duration underlines the need to investigate long-term effects of psychotropic drug use in children with ASD.


Author(s):  
Christine Leong ◽  
Laurence Y. Katz ◽  
James M. Bolton ◽  
Murray W. Enns ◽  
Joseph Delaney ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document